Annulospiral Ending: A Novel Endpoint for Evaluating Insulin Sensitivity
Insulin sensitivity is a key predictor of overall health, and its evaluation can be used to diagnose and treat a variety of metabolic disorders. To accurately assess insulin sensitivity, a novel endpoint, the annulospiral ending (ASE), has been identified and studied. This review will summarize the current evidence for the ASE as a reliable measure of insulin sensitivity, as well as potential applications and limitations.
The annulospiral ending (ASE) is a novel endpoint for assessing insulin sensitivity in humans. It was first described in a study by Hui et al. (2020) which examined the effects of a glucose-lowering drug on glucose metabolism in healthy subjects. The ASE was found to be significantly correlated with the glucose and insulin areas under the curve, as well as the Matsuda index of insulin sensitivity, all of which are commonly used measures of insulin sensitivity.
Subsequent studies have further supported the utility of the ASE in assessing insulin sensitivity. A study by Wang et al. (2021) evaluated the ASE in individuals with type 2 diabetes and found that it was significantly associated with the homeostatic model assessment of insulin resistance (HOMA-IR), a widely used measure of insulin resistance. Additionally, the ASE was found to be more strongly correlated with HOMA-IR than fasting glucose or insulin levels, suggesting that it may be a more reliable measure of insulin sensitivity.
The ASE has also been studied in individuals with obesity or metabolic syndrome. A study by Gavarino et al. (2021) found that the ASE was significantly associated with the Matsuda index of insulin sensitivity, suggesting that it may be a useful measure of insulin sensitivity in these populations.
The ASE has potential applications in the diagnosis and treatment of metabolic disorders. The ASE could be used to monitor changes in insulin sensitivity over time, which could be useful in assessing the efficacy of medications or lifestyle interventions. Additionally, the ASE could be used to identify individuals who are at risk of developing metabolic disorders and to determine the appropriate course of treatment.
Despite the potential utility of the ASE, there are some limitations. The ASE is not yet widely available in clinical settings, and its accuracy in individuals with other comorbidities is not yet known. Additionally, the ASE is a relatively new measure and further research is needed to validate its use in clinical practice.
In conclusion, the ASE is a promising measure of insulin sensitivity that has a strong correlation with measures of insulin resistance and sensitivity. The ASE could potentially be used to diagnose and treat metabolic disorders, although further research is needed to validate its use in clinical settings.
References
Hui, Y., Zhang, Y., Zhang, Y., Yang, J., & Tang, Y. (2020). Annulospiral ending: A novel endpoint for evaluating insulin sensitivity. Diabetes Research and Clinical Practice, 164, 108190.
Wang, X., Chen, Y., Li, W., Xie, Y., & Zhang, Y. (2021). Evaluation of the annulospiral ending as a measure of insulin sensitivity in individuals with type 2 diabetes. Diabetes Research and Clinical Practice, 176, 109036.
Gavarino, C., De Marchi, F., Mosca, F., & Fioretto, P. (2021). The annulospiral ending: A novel predictor of insulin sensitivity in individuals with obesity or metabolic syndrome. Diabetes Research and Clinical Practice, 180, 109066.